{"id":"elizaria","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, Elizaria modulates the sphingosine-1-phosphate (S1P) signaling pathway, which plays a crucial role in immune cell trafficking and lymphocyte egress from lymphoid organs.","oneSentence":"Elizaria is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:39.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04671810","phase":"","title":"Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-06-13","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":44},{"nctId":"NCT04749810","phase":"","title":"Observational Study of Elizaria® in aHUS Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2019-12-19","conditions":"Atypical Hemolytic Uremic Syndrome, aHUS","enrollment":50},{"nctId":"NCT04463056","phase":"PHASE3","title":"Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2017-11-29","conditions":"Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome, Paroxysmal Hemoglobinuria","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eculizumab","eculizumab"],"phase":"phase_3","status":"active","brandName":"Elizaria®","genericName":"Elizaria®","companyName":"AO GENERIUM","companyId":"ao-generium","modality":"Biologic","firstApprovalDate":"","aiSummary":"Elizaria is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}